TWI790191B - 用於病患口服之含砷高表面積冷凍乾燥組合物 - Google Patents

用於病患口服之含砷高表面積冷凍乾燥組合物 Download PDF

Info

Publication number
TWI790191B
TWI790191B TW105103175A TW105103175A TWI790191B TW I790191 B TWI790191 B TW I790191B TW 105103175 A TW105103175 A TW 105103175A TW 105103175 A TW105103175 A TW 105103175A TW I790191 B TWI790191 B TW I790191B
Authority
TW
Taiwan
Prior art keywords
minutes
mtorr
product
powder
as2o3
Prior art date
Application number
TW105103175A
Other languages
English (en)
Chinese (zh)
Other versions
TW201642879A (zh
Inventor
克里旭納 法迪
庫瑪 庫魯馬達里
Original Assignee
美商錫羅斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商錫羅斯製藥公司 filed Critical 美商錫羅斯製藥公司
Publication of TW201642879A publication Critical patent/TW201642879A/zh
Application granted granted Critical
Publication of TWI790191B publication Critical patent/TWI790191B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105103175A 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物 TWI790191B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562110574P 2015-02-01 2015-02-01
US62/110,574 2015-02-01
US201562142709P 2015-04-03 2015-04-03
US62/142,709 2015-04-03

Publications (2)

Publication Number Publication Date
TW201642879A TW201642879A (zh) 2016-12-16
TWI790191B true TWI790191B (zh) 2023-01-21

Family

ID=56544541

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105103175A TWI790191B (zh) 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物
TW111149127A TW202337477A (zh) 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物
TW110142380A TW202228734A (zh) 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111149127A TW202337477A (zh) 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物
TW110142380A TW202228734A (zh) 2015-02-01 2016-02-01 用於病患口服之含砷高表面積冷凍乾燥組合物

Country Status (20)

Country Link
US (6) US10111836B2 (enExample)
EP (3) EP3981414B1 (enExample)
JP (3) JP6928768B2 (enExample)
CN (2) CN107530373B (enExample)
AU (4) AU2016211186A1 (enExample)
CA (2) CA2975406C (enExample)
DK (1) DK3981414T3 (enExample)
ES (2) ES3034734T3 (enExample)
FI (1) FI3981414T3 (enExample)
HR (1) HRP20251032T1 (enExample)
HU (1) HUE072537T2 (enExample)
LT (1) LT3981414T (enExample)
MX (2) MX390835B (enExample)
PL (1) PL3981414T3 (enExample)
PT (1) PT3981414T (enExample)
RS (1) RS67133B1 (enExample)
SI (1) SI3981414T1 (enExample)
SM (1) SMT202500321T1 (enExample)
TW (3) TWI790191B (enExample)
WO (1) WO2016123603A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975406C (en) 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS
US20260027056A1 (en) * 2015-02-01 2026-01-29 Quetzal Therapeutics, Llc High surface-area lyophilized compositions comprising arsenic for oral administration in patients
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
US20190374611A1 (en) * 2017-01-18 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US12582984B1 (en) 2020-07-02 2026-03-24 Argonaut Manufacturing Services, Inc. Method for lyophilization and device thereof
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
JP7428842B1 (ja) 2023-03-29 2024-02-06 ａｒｔｉｅｎｃｅ株式会社 活性エネルギー線硬化型インキ、その製造方法、および印刷物
AU2025223378A1 (en) * 2024-02-14 2026-07-30 Assistance Publique - Hôpitaux De Paris Oral composition of arsenic trioxide for cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
CN101322719A (zh) * 2007-06-15 2008-12-17 杭州民生药业集团有限公司 一种三氧化二砷固体脂质纳米粒、其制剂及其制备方法
CN103142648A (zh) * 2011-12-07 2013-06-12 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773419A (en) 1995-03-03 1998-06-30 Falcon; Juan Method of treating cancer with tannic acid
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7276359B1 (en) * 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
CN1131922C (zh) 1998-10-19 2003-12-24 张在喆 一种通过弹性键搭架与收拢的帐篷
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CN102772413A (zh) * 2000-02-29 2012-11-14 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
US8906422B2 (en) 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CN1251688C (zh) 2003-12-09 2006-04-19 重庆维特瑞医药开发有限公司 三氧化二砷冻干粉针及其生产方法
JP4292985B2 (ja) 2003-12-25 2009-07-08 Ｊｓｒ株式会社 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子
CN1698650A (zh) 2004-05-21 2005-11-23 哈尔滨伊达药业有限公司 一种治疗原发性肝癌的亚砷酸注射液及其制备方法
CN1326528C (zh) 2004-07-13 2007-07-18 东南大学 砒霜磁性纳米明胶微球的制备工艺
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
US20110165259A1 (en) 2008-09-19 2011-07-07 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
EP2525783A1 (en) 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
CN103408477B (zh) 2013-08-22 2015-06-10 陈鹏飞 一种含砷配位化合物及其制备方法
PL3250213T3 (pl) 2015-01-29 2023-10-30 Eupharma Pty Ltd Kompozycje zawierające arsen do stosowania w sposobach leczenia
CA2975406C (en) 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
CN101322719A (zh) * 2007-06-15 2008-12-17 杭州民生药业集团有限公司 一种三氧化二砷固体脂质纳米粒、其制剂及其制备方法
CN103142648A (zh) * 2011-12-07 2013-06-12 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂

Also Published As

Publication number Publication date
CA2975406C (en) 2025-07-22
SMT202500321T1 (it) 2025-11-10
EP3250214B1 (en) 2021-09-01
EP3981414B1 (en) 2025-06-25
US20230310325A1 (en) 2023-10-05
HUE072537T2 (hu) 2025-11-28
JP6928768B2 (ja) 2021-09-01
NZ772450A (en) 2024-07-05
US12364664B2 (en) 2025-07-22
JP2021152059A (ja) 2021-09-30
MX390835B (es) 2025-03-21
US20200060974A1 (en) 2020-02-27
JP2018503696A (ja) 2018-02-08
US20160235679A1 (en) 2016-08-18
LT3981414T (lt) 2025-09-25
TW202337477A (zh) 2023-10-01
EP3250214A4 (en) 2018-09-19
AU2016211186A1 (en) 2017-08-17
US10111836B2 (en) 2018-10-30
CA2975406A1 (en) 2016-08-04
FI3981414T3 (fi) 2025-07-29
HK1248113A1 (zh) 2018-10-12
PL3981414T3 (pl) 2025-10-06
JP7539855B2 (ja) 2024-08-26
MX2017009913A (es) 2018-08-15
US10272045B2 (en) 2019-04-30
CN117899029A (zh) 2024-04-19
AU2025259861A1 (en) 2025-11-20
JP7885288B2 (ja) 2026-07-06
AU2021203752A1 (en) 2021-07-08
MX2020012611A (es) 2021-02-09
AU2023214307B2 (en) 2025-08-21
CN107530373B (zh) 2023-12-29
ES3034734T3 (en) 2025-08-22
AU2023214307A1 (en) 2023-08-31
ES2899226T3 (es) 2022-03-10
TW201642879A (zh) 2016-12-16
WO2016123603A2 (en) 2016-08-04
US20190029963A1 (en) 2019-01-31
EP3250214A2 (en) 2017-12-06
US10653628B2 (en) 2020-05-19
JP2024161468A (ja) 2024-11-19
CN107530373A (zh) 2018-01-02
CA3225480A1 (en) 2016-08-04
DK3981414T3 (da) 2025-07-14
WO2016123603A3 (en) 2016-11-03
PT3981414T (pt) 2025-07-22
TW202228734A (zh) 2022-08-01
SI3981414T1 (sl) 2025-10-30
HRP20251032T1 (hr) 2025-10-24
EP4599823A1 (en) 2025-08-13
RS67133B1 (sr) 2025-09-30
US20210069115A1 (en) 2021-03-11
NZ734201A (en) 2024-03-22
EP3981414A1 (en) 2022-04-13
AU2021203752B2 (en) 2023-08-31
US20240269076A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
JP7539855B2 (ja) 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
EP3938368B1 (en) Compound form having enhanced bioavailability and formulations thereof
US20260027056A1 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
HK40129981A (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
HK40073108A (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
CN104398501B (zh) 用于治疗易复发性癌症的聚合物胶束组合物及其制备方法
HK1248113B (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
EA046804B1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы
HK40005153A (en) Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses